Bruderman Asset Management LLC Increases Position in Sanofi (SNY)

Bruderman Asset Management LLC boosted its position in Sanofi (NYSE:SNY) by 33.0% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 205,680 shares of the company’s stock after buying an additional 51,081 shares during the period. Sanofi comprises 2.7% of Bruderman Asset Management LLC’s portfolio, making the stock its 14th largest position. Bruderman Asset Management LLC’s holdings in Sanofi were worth $9,307,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the company. Dodge & Cox acquired a new stake in shares of Sanofi during the fourth quarter worth $2,770,485,000. Fisher Asset Management LLC raised its stake in shares of Sanofi by 1.0% in the first quarter. Fisher Asset Management LLC now owns 12,615,505 shares of the company’s stock valued at $570,852,000 after buying an additional 123,470 shares during the period. Wells Fargo & Company MN raised its stake in shares of Sanofi by 22.2% in the first quarter. Wells Fargo & Company MN now owns 4,492,719 shares of the company’s stock valued at $203,296,000 after buying an additional 815,820 shares during the period. Hamlin Capital Management LLC raised its stake in shares of Sanofi by 11.8% in the first quarter. Hamlin Capital Management LLC now owns 1,768,523 shares of the company’s stock valued at $80,026,000 after buying an additional 186,280 shares during the period. Finally, Parametric Portfolio Associates LLC increased its position in shares of Sanofi by 25.3% in the first quarter. Parametric Portfolio Associates LLC now owns 1,460,280 shares of the company’s stock valued at $66,078,000 after buying an additional 295,242 shares in the last quarter. Institutional investors and hedge funds own 9.86% of the company’s stock.

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Shares of Sanofi (NYSE:SNY) traded down 0.08% during midday trading on Friday, hitting $47.73. 1,511,331 shares of the company’s stock traded hands. The firm has a market capitalization of $120.54 billion, a price-to-earnings ratio of 11.87 and a beta of 0.93. Sanofi has a 1-year low of $36.81 and a 1-year high of $50.24. The company has a 50 day moving average price of $48.76 and a 200 day moving average price of $43.98.

Sanofi (NYSE:SNY) last issued its quarterly earnings data on Friday, April 28th. The company reported $0.76 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.03. Sanofi had a net margin of 26.55% and a return on equity of 25.89%. The company had revenue of $8.65 billion for the quarter, compared to analyst estimates of $8.40 billion. The firm’s revenue was up 1.2% compared to the same quarter last year. Equities analysts anticipate that Sanofi will post $3.15 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This report was first reported by Transcript Daily and is owned by of Transcript Daily. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://transcriptdaily.com/2017/06/17/sanofi-sa-sny-stake-increased-by-bruderman-asset-management-llc-updated-updated.html.

Several brokerages recently issued reports on SNY. BidaskClub downgraded Sanofi from a “buy” rating to a “hold” rating in a research report on Friday, June 9th. Argus upped their price objective on Sanofi from $50.00 to $55.00 and gave the stock a “buy” rating in a report on Friday, June 9th. Berenberg Bank downgraded Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, May 11th. Zacks Investment Research raised shares of Sanofi from a “hold” rating to a “buy” rating and set a $55.00 price target for the company in a research report on Friday, June 2nd. Finally, J P Morgan Chase & Co reaffirmed a “sell” rating on shares of Sanofi in a research report on Thursday, March 30th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have assigned a buy rating to the company’s stock. Sanofi presently has an average rating of “Hold” and an average price target of $67.67.

About Sanofi

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply